Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Hizentra Market Expected To Reach $ Billion By 2030 At % CAGR
The expansion observed during the historical period was driven by several key factors, such as the constraints associated with IVIG treatment administered in hospital settings, the rising frequency of primary immunodeficiency cases, the demonstrated clinical effectiveness of SCIG therapies, the growing preference for home-based care solutions, and enhanced levels of patient compliance with treatment regimens.
The expansion of home healthcare services, a rise in immune disorder diagnoses, growing demand for long-term replacement therapy, technological improvements in infusion devices, and favorable reimbursement for SCIG are key factors expected to drive growth during the forecast period. Within this timeframe, significant developments include a transition to subcutaneous immunoglobulin treatment, increased adoption of home-based immunodeficiency care, a preference for adaptable self-administered dosing schedules, broader availability of extended immunoglobulin replacement regimens, and heightened emphasis on enhancing patients’ overall quality of life.
Download A Free Sample Report For Comprehensive Market Insights:
Hizentra Market Demand Drivers Creating New Revenue Opportunities
A notable rise in autoimmune disorders is set to drive growth in the Hizentra market. These are medical conditions in which the immune system erroneously targets and attacks the body’s own healthy cells, tissues, or organs. An escalating incidence of these disorders can be attributed to a convergence of genetic, environmental, and lifestyle elements, such as greater exposure to environmental toxins, changes in dietary habits, and reduced contact with pathogens. Hizentra is administered in such cases to supply immunoglobulin replacement therapy, which assists in modulating immune activity and easing associated symptoms. A study published in May 2023 by the NIHR Imperial Biomedical Research Centre, a UK government research body, analyzed anonymized electronic health records from 22 million individuals. It found that 19 common autoimmune diseases impact approximately 10% of the UK population, including 13% of women and 7% of men. This increase in autoimmune diseases is consequently fueling demand within the Hizentra market.
Rising healthcare spending is anticipated to be a key driver of growth for the Hizentra market. This term describes the overall financial resources allocated to healthcare services, products, and related initiatives, covering everything from prevention and diagnosis to the treatment and management of various health issues. This expenditure is climbing due to several influences, including an aging population, progress in medical technology, a growing prevalence of chronic conditions, and higher costs for pharmaceuticals and medical services. Greater financial investment in healthcare improves both the accessibility and affordability of Hizentra, enabling better support for patients dealing with primary immunodeficiency and related conditions. Data from May 2024, provided by the UK-based Office for National Statistics, showed that total healthcare expenditure increased by 5.6% in nominal terms between 2022 and 2023. This marks a significant acceleration when compared to the 0.9% growth recorded in 2022. Therefore, this sustained rise in healthcare expenditure is propelling forward momentum for the Hizentra market.
Hizentra Market Categorization By Product Type And Application
The hizentra market covered in this report is segmented –
1) By Product Type: Subcutaneous Immunoglobulin (SCIg), Intravenous Immunoglobulin (IVIg)
2) By Indication: Primary Immunodeficiency (PI), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
3) By Distribution Channel: Hospitals, Specialty Pharmacies, Home Healthcare Providers, Retail Pharmacies
Hizentra Market Trends Driving Strategic Industry Expansion
A central driver in the hizentra market involves the push toward creating cutting-edge products, with prefilled syringes emerging as a key example, to secure a stronger foothold in the sector. These syringes are single-use devices already filled with a predetermined medication dose, which guarantees precise administration and cuts down on the time needed for preparation. Constructed usually from glass or plastic, they are built to be easy to handle whether used for self-injection or within a medical environment. For example, in April 2023, CSL Behring, a biotechnology firm based in the United States, revealed that the FDA had granted approval for a 50 mL/10 g prefilled syringe tailored for Hizentra (immune globulin subcutaneous [human] 20% Liquid). As a result of this development, CSL Behring now provides a full array of prefilled syringe sizes, each designed to meet the distinct requirements of individuals battling primary immunodeficiency (PI) or chronic inflammatory demyelinating polyneuropathy (CIDP). Notably, Hizentra stands as the sole immune globulin (Ig) available in a user-friendly, ready-to-administer prefilled syringe format.
Hizentra Market Company Landscape And Strategic Competition
Major companies operating in the hizentra market are CSL Behring
Access The Complete Hizentra Market Report:
Hizentra Market Regional Analysis And Leading Geography
North America was the largest region in the hizentra market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hizentra market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model